The impact of rare disease: real-world evidence on burden and treatment gaps in commercial and Medicare patients with acromegaly

This webinar will bring together clinical and industry perspectives to share new real-world evidence on the burden, treatment patterns, and dosing patterns associated with acromegaly, highlight unmet need, and uncover opportunities for more effective care.

Acromegaly is a rare disease that patients experience following the growth of a pituitary tumor. Patients with acromegaly experience increased morbidity (e.g., soft tissue growth, joint pain, arthritis, diabetes, hypertension, sleep apnea) and mortality relative to patients without acromegaly.

New research using US claims data reveals the magnitude of acromegaly's burden and highlights increased healthcare resource utilization, increased healthcare costs, and poor medication persistence. Coupled with patient-reported outcomes from survey-based studies, these findings underscore the need for effective, tolerable, and patient-centered treatment strategies. 

Of specific interested for: Researchers interested in real-world data
Patients with acromegaly and their families
Payers
Physicians
Other healthcare providers

Your details

By submitting this form you are agreeing to our Terms & Conditions and Privacy Policy, and agree to receiving relevant emails from The Evidence Base about the latest news and editorial features.

Terms & Conditions

I agree to receive third party emails to keep me informed of relevant products and services relevant to my industry.

By registering for this webinar you agree for your registration data to be transferred to the sponsoring organizations (Advi and Crinetics Pharmaceuticals), who may contact you from time to time regarding relevant products and services. You can unsubscribe at any time.

Subscribing to

Confirm sign-up

What you will learn:

How the pathophysiology of acromegaly contributes to disease burden and long-term health outcomes.
The strengths and limitations of using claims data to study rare diseases in real-world settings.
What types of data are needed to understand the experience of individuals diagnosed with acromegaly and other rare diseases.
Key findings from peer-reviewed, real-world studies on disease burden, treatment patterns, and dosing patterns in patients with acromegaly.

Speakers:

Tiffany P Quock, PhD, MS
Vice President, Health Economics and Outcomes Research, Crinetics Pharmaceuticals

Tiffany P Quock, PhD, MS is an epidemiologist and health economist with 20 years of experience in drug development. She is currently the Vice President, Health Economics and Outcomes Research at Crinetics Pharmaceuticals, and was previously Head of Global HEOR and Medical Affairs at Prothena Biosciences. She started her career as a Visiting Assistant Professor at UCLA School of Medicine and has experience across a multitude of therapeutic areas, including rare diseases, neuroscience, and oncology. She obtained her PhD and MS at UCLA, and completed fellowships at UCSF, RAND, and in Entrepreneurship at Stanford University Graduate School of Business.

Michael S Broder, MD, MSHS
Chief Economist, ADVI Health

Dr Michael Broder has 30 years of experience in health economics and outcomes research (HEOR). He is a graduate of Harvard, a graduate of Case Western Reserve University Medical School, and a board-certified obstetrician-gynecologist. Before entering the industry, he was on the full-time faculty at the UCLA School of Medicine and a grant-funded researcher RAND. Dr Broder has conducted research for industry, specialty societies, and government on a wide range of topics using diverse health service research methods. He has published over one hundred articles in peer-reviewed journals and is the author of two books and multiple book chapters.

Moderator:

Laura Dormer
Editor, The Evidence Base
Editor in Chief, Journal of Comparative Effectiveness Research
Editorial Director, Becaris Publishing

Share this webinar